Skip to content
Injection Allopathic

Cosentyx 150 mg/ml injection

Generic: Secukinumab

Company: Not listed yet. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength150 mg/ml
PackNot listed yet

Reviewed by: not listed yet. Source: not listed yet.

Last updated September 7, 2024.

Compare

Same generic, same strength

Sorted by price per injection. Ask your pharmacist before you switch brands.

Secukinumab 150 mg/ml injections

Prices as listed on BestinMeds.

No price is listed for this strength yet.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Secukinumab guide

Indications

Rheumatoid arthritis Secukinumab is a human interleukin-17A antagonist indicated for the treatment of: Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Adults with active psoriatic arthritis (PsA) Adults with active ankylosing spondylitis (AS)

Dosage and administration

Plaque Psoriasis- 1. Recommended dosage is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. For some patients, a dose of 150 mg may be acceptable. Psoriatic Arthritis- 1. For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosage and administration for plaque psoriasis. 2. For other psoriatic arthritis patients administer with or without a loading dosage. The recommended dosage: With a loading dosage is 150 mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter Without a loading dosage is 150 mg every 4 weeks If a patient continues to have active psoriatic arthritis, consider a dosage of 300 mg. Ankylosing Spondylitis- 1. Administer with or without a loading dosage. The recommended dosage: With a loading dosage is 150 mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter Without a loading dosage is 150 mg every 4 weeks

Side effects

Most common adverse reactions (greater than 1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.

Precautions and warnings

Infections: Serious infections have occurred. Caution should be exercised when considering the use of secukinumab in patients with a chronic infection or a history of recurrent infection. If a serious infection develops, discontinue secukinumab until the infection resolves. Tuberculosis (TB): Prior to initiating treatment with secukinumab, evaluate for TB. Inflammatory Bowel Disease: Cases of inflammatory bowel disease were observed in clinical trials. Caution should be exercised when prescribing secukinumab to patients with inflammatory bowel disease. Hypersensitivity Reactions: If an anaphylactic reaction or other serious allergic reaction occurs, discontinue secukinumab immediately and initiate appropriate therapy.

Pregnancy and lactation

Pregnancy: Limited available human data with secukinumab use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. In an embryo-fetal development study, no adverse developmental effects were observed in infants born to pregnant monkeys after subcutaneous administration of secukinumab during organogenesis at doses up to 30 times the maximum recommended human dose Lactation: It is not known whether secukinumab is excreted in human milk or absorbed systemically after ingestion. There are no data on the effects of secukinumab on the breastfed child or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for secukinumab and any potential adverse effects on the breastfed child from secukinumab or from the underlying maternal condition.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250